Modified cascade ribonucleoproteins and uses thereof
Inventors
Brouns, Stan Johan Jozef • Van Der Oost, John
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
A clustered regularly interspaced short palindromic repeat (CRISPR)-associated complex for adaptive antiviral defence (Cascade); the Cascade protein complex comprising at least CRISPR-associated protein subunits Cas7, Cas5 and Cas6 which includes at least one subunit with an additional amino acid sequence possessing nucleic acid or chromatin modifying, visualising, transcription activating or transcription repressing activity. The Cascade complex with additional activity is combined with an RNA molecule to produce a ribonucleoprotein complex. The RNA molecule is selected to have substantial complementarity to a target sequence. Targeted ribonucleoproteins can be used as genetic engineering tools for precise cutting of nucleic acids in homologous recombination, non-homologous end joining, gene modification, gene integration, mutation repair or for their visualisation, transcriptional activation or repression. A pair of ribonucleotides fused to FokI dimers may be used to generate double-strand breakages in the DNA to facilitate these applications in a sequence-specific manner.
Core Innovation
The disclosure describes a Type I CRISPR composition comprising a Type I CASCADE protein complex with a Cse1 subunit protein, an Escherichia coli Cas3 mutant protein, and a crRNA molecule. The Cas3 mutant protein is fused to the N-terminus of the Cse1 subunit protein by a linker polypeptide, and the crRNA contains a spacer sequence complementary to a target nucleic acid. An expression vector encoding these components is also described.
The fusion retains in vivo phage-resistance activity and target-specific in vitro DNA nicking, with Cascade preferentially binding negatively supercoiled target DNA and interacting with Cas3 upon target recognition. The disclosure further describes plasmid degradation, paired Cascade-FokI complexes for targeted double-strand breaks and genome editing, and functional fusions for modifying, visualizing, or regulating target nucleic acids.
Claims Coverage
The claims identify two inventive features across two independent claims, covering a Type I CRISPR composition and an expression vector encoding the composition.
Type I CRISPR composition with a Cas3 mutant fused to Cse1
A Type I CASCADE protein complex comprising a Cse1 subunit protein, an Escherichia coli Cas3 mutant protein fused to the N-terminus of the Cse1 subunit protein by a linker polypeptide, and a crRNA molecule comprising a spacer sequence complementary to a target nucleic acid.
Expression vector encoding Type I CRISPR components
An expression vector comprising a nucleic acid sequence encoding a Type I CASCADE protein complex comprising a Cse1 subunit protein, an Escherichia coli Cas3 mutant protein fused to the N-terminus of Cse1 by a linker polypeptide, and a crRNA molecule comprising a spacer sequence complementary to a target nucleic acid.
The claim elements collectively protect the Cas3 mutant-Cse1 fusion within a Type I CRISPR composition and an expression vector encoding these components.
Stated Advantages
Not explicitly described in patent.
Documented Applications
Targeted double-strand breaks, DNA cleavage, and genome editing using paired Cascade-FokI nuclease complexes.
Modifying, visualizing, or regulating target nucleic acids using functional fusions.
CRISPR-dependent phage targeting conferring phage resistance.
Interested in licensing this patent?